Adicet Bio, Inc. cash flow to debt ratio of -646.26% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Adicet Bio, Inc.'s free cash flow has decreased 3.73% from $-93.50M last year to $-96.98M, signaling decreasing performance

Adicet Bio, Inc.'s debt to equity ratio is 0.11, which means that the company's assets are healthy financed, signaling financial stability.

Adicet Bio, Inc.'s debt has increased relative to shareholder equity from 0.09 last year to 0.11 today, signaling weakened financials

Adicet Bio, Inc. has a net cash position, so leverage is healthy.

Adicet Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Adicet Bio, Inc. has insufficient data to evaluate this check.

Adicet Bio, Inc.'s short-term assets of $160.93M exceed its short-term liabilities of $21.53M

Adicet Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Adicet Bio, Inc.'s return on equity of -74.90%, is lower than 15.00%, indicating bad performance

Adicet Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Adicet Bio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Adicet Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Adicet Bio, Inc. has negative free cash flow, indicating cash burn

Adicet Bio, Inc.'s yearly earnings has increased -0.27% since last year from $-117.12M to $-116.80M, signaling increasing performance

Adicet Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -77.98% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Adicet Bio, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Adicet Bio, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Adicet Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Adicet Bio, Inc. has insufficient data to evaluate this check.

Adicet Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Adicet Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Adicet Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Adicet Bio, Inc. has insufficient data to evaluate this check.

Adicet Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Adicet Bio, Inc. has a price-to-book ratio of 0.73x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Adicet Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue